Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Monoclonal antibody | 4 |
Recombinant polypeptide | 3 |
AAV based gene therapy | 3 |
Recombinant protein | 2 |
Target |
Mechanism RNA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism STAT3 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MEG3 agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Jul 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator ![]() [+3] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ND7(New York University) ( PGRN ) | Parkinson Disease More | Preclinical |
GL-12 | Cardiovascular Diseases More | Preclinical |
MPC309 ( AR ) | Prostatic Cancer More | Preclinical |
KTX-115 ( STAT3 ) | Cutaneous T-Cell Lymphoma More | Preclinical |
ARN-2966 ( RNA ) | Alzheimer Disease More | Preclinical |